Anaplastic Oligoastrocytoma

Other names
Types
Causes and contributing factors
Common symptoms
Diagnostic tests
Non-pharmacological treatments
Drug treatments
Dietary molecular supplements
Immunity-booster / regenerative / stem-cell drugs
Surgeries
Prevention tips
When to see a doctor (red flags)
What to eat and what to avoid
Frequently asked questions

Anaplastic oligoastrocytoma was the old name for a malignant (fast-growing) brain tumor that looked like a mix of two cell types: astrocytes and oligodendrocytes. Modern testing shows almost all of these “mixed” tumors are actually one of two things: (1) an astrocytoma, IDH-mutant (and not 1p/19q-codeleted), or (2) an oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Because of this, the World Health Organization (WHO) removed “oligoastrocytoma” (and “anaplastic oligoastrocytoma”) from its current brain-tumor classification. Care teams now diagnose and treat based on the molecular type (IDH status, 1p/19q codeletion) rather than the old mixed label. This change improves accuracy for prognosis and treatment choice. Radiopaedia+4PMC+4PMC+4

“Anaplastic oligoastrocytoma” was an old name for a fast-growing (grade 3) brain tumor that looked like a mix of two glial tumors under the microscope: an astrocytoma and an oligodendroglioma. “Anaplastic” means the cells look aggressive and divide quickly. Today, doctors rarely use this label. Since 2016—and reinforced in 2021—the World Health Organization (WHO) tells doctors to classify these tumors by their genes (molecular markers), not just by how they look. With modern testing, almost all tumors that once looked “mixed” turn out to be either an astrocytoma, IDH-mutant or an oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Only in very rare situations is a true, dual-genotype “mixed” tumor seen. So if you still see “anaplastic oligoastrocytoma” in a report, it usually means molecular testing was not available or it is a legacy label. SpringerLink+2PMC+2

Other names

You may also see: “mixed anaplastic glioma,” “anaplastic mixed glioma,” “oligoastrocytoma, WHO grade III,” “AOA,” or “oligoastrocytoma-NOS (not otherwise specified).” These are historical or fallback terms used when genetic testing is missing or inconclusive. Current guidance strongly discourages using these terms when modern molecular testing can be done. SpringerLink

Types

Today, a tumor that once might have been called “anaplastic oligoastrocytoma” is re-assigned to one of these WHO 2021 adult-type diffuse glioma categories, based on molecular testing:

Astrocytoma, IDH-mutant (CNS WHO grade 2-4) — If the tumor has an IDH1/IDH2 mutation and no 1p/19q codeletion (often with ATRX loss and TP53 mutation). Grade 3 astrocytomas correspond to the old “anaplastic” behavior. PMC+1
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (CNS WHO grade 2-3) — Must have both an IDH mutation and combined whole-arm losses of chromosome 1p and 19q. Grade 3 oligodendrogliomas correspond to the old “anaplastic” behavior. PMC
Very rare “dual-genotype” mixed gliomas — Uncommon tumors with spatially distinct astrocytic and oligodendroglial components each carrying its own matching genotype. These are exceptional case reports; routine use of “oligoastrocytoma” is discouraged. SpringerLink+1

Causes and contributing factors

For brain gliomas in adults, a single lifestyle cause is not known. High-dose ionizing radiation and a few inherited syndromes raise risk. At the tumor level, certain gene changes “drive” growth. Below are risk factors and biological drivers explained in easy language.

High-dose ionizing radiation (for example, prior therapeutic radiation to the head) raises risk of developing brain tumors, including gliomas. American Cancer Society
Family history of glioma slightly increases risk, though most cases are sporadic (happen by chance). American Cancer Society
Li-Fraumeni syndrome (TP53) is a rare inherited condition that can predispose to gliomas. Cancer.gov
Lynch/Turcot syndrome (MMR genes) can be associated with gliomas in some families. Cancer.gov
Neurofibromatosis type 1 (NF1) increases risk for certain gliomas (especially optic pathway), showing that inherited gene changes can set the stage for glioma growth. Cancer.gov
Tuberous sclerosis (TSC1/TSC2) is another tumor-predisposition syndrome linked to specific CNS tumors, reflecting how genetic pathways can drive growth. Cancer.gov
Cowden syndrome (PTEN) and other PTEN-hamartoma syndromes can involve brain tumors, again illustrating inherited pathway risk. Cancer.gov
Age — Adult-type diffuse gliomas are more common in mid- to later-adulthood than in children, reflecting different disease biology by age. PMC
IDH1/IDH2 mutations — Not a “risk factor” you can see in advance, but a key driver within the tumor that shapes behavior and prognosis once the tumor exists. PMC
1p/19q codeletion — A defining change for oligodendroglioma; it influences response to therapy and outlook once the tumor exists. PMC
ATRX loss — Common in IDH-mutant astrocytoma and helps separate astrocytoma from oligodendroglioma. SpringerLink
TP53 mutation — Also common in IDH-mutant astrocytoma and part of its molecular fingerprint. SpringerLink
TERT promoter mutation — Often seen in oligodendroglioma and impacts telomere maintenance (a growth advantage). PMC
MGMT promoter methylation — Not a cause, but a tumor feature that predicts better response to alkylating chemotherapy; it shapes management once a tumor exists. Cancer.gov
Progression from a lower-grade diffuse glioma — Some grade 2 gliomas acquire changes over time that make them “anaplastic” (grade 3). SpringerLink
Most environmental/lifestyle exposures (like cell phones, routine chemicals) have not shown clear, consistent links to glioma in adults. American Cancer Society
Weakened immune system is a general brain-tumor risk topic, but it is far more strongly tied to primary CNS lymphoma than to diffuse gliomas. (Included here to clarify a common confusion.) American Cancer Society
Biologic sex and ancestry patterns may shift overall CNS tumor rates, but they do not point to a single controllable cause for gliomas. NINDS
Pediatric vs adult biology — Children’s diffuse gliomas use different gene pathways than adult-type gliomas, explaining why adult-type tumors appear more in adults. PMC
Unknown factors — For most patients, no trigger is found; research continues to seek causes and prevention. American Cancer Society

Common symptoms

Symptoms depend on where the tumor sits and how quickly it grows. Any single person may have only a few of these.

Seizures — A common first sign in diffuse gliomas, due to abnormal electrical activity in the affected cortex. American Cancer Society
Headache — Often dull or worse in the morning; sometimes linked to pressure changes in the skull. American Cancer Society
Weakness of an arm or leg — If the tumor affects motor areas, you may notice clumsiness or true weakness on one side. American Cancer Society
Numbness or tingling — Sensory areas can be involved, causing altered feeling on one side. American Cancer Society
Speech or language problems — Trouble finding words, understanding speech, or forming clear sentences if language areas are involved. American Cancer Society
Vision problems — Blurred vision, visual field loss, or double vision, depending on pathways affected. American Cancer Society
Balance or coordination problems — Unsteady walking, poor finger-to-nose testing, or frequent falls if cerebellar networks are affected. American Cancer Society
Personality or behavior change — Irritability, apathy, or poor judgment with frontal lobe involvement. American Cancer Society
Memory or thinking issues — Difficulty concentrating, planning, or remembering. American Cancer Society
Nausea and vomiting — Can occur with raised intracranial pressure. American Cancer Society
Fatigue and sleepiness — General slowing or increased need for sleep. American Cancer Society
Hearing changes or tinnitus — If temporal lobe or related pathways are affected. American Cancer Society
Facial weakness or droop — From involvement of motor pathways or pressure effects. American Cancer Society
Papilledema (swollen optic discs) — A doctor may see this sign of raised pressure on eye exam; not everyone has it. EyeWiki+1
Sudden neurologic events — Rarely, bleeding into a tumor or acute swelling can cause abrupt worsening. American Cancer Society

Diagnostic tests

A) Physical examination (bedside and office checks)

Full neurologic exam — Tests mental status, cranial nerves, strength, reflexes, sensation, coordination, and gait. Abnormal findings point to where in the brain the problem may be, guiding imaging. NCBI+1
Cognitive screening (e.g., quick bedside tests) — Simple tasks check attention, memory, and language; they help map deficits to tumor location. NCBI
Visual field confrontation — The clinician checks if parts of the visual field are missing, which can localize occipital or optic-pathway involvement. NCBI
Gait and coordination assessment — Walking tests and finger-to-nose checks reveal cerebellar or frontal lobe issues. NCBI
Fundoscopic (eye) exam for papilledema — Looking at the optic nerve in the eye can show swelling from raised pressure; this is an urgent clue that prompts careful imaging. Stanford Medicine+1

B) “Manual” bedside maneuvers (simple hands-on tests)

Romberg test — Standing with feet together, eyes closed, to check balance pathways; sway suggests sensory or cerebellar problems. NCBI
Pronator drift — Arms outstretched and eyes closed; downward drift of one arm can indicate subtle weakness from a brain lesion. NCBI+1
Finger-to-nose / heel-to-shin — Coordination tests that expose cerebellar or pathway dysfunction. Stroke Manual
Rapid alternating movements — Difficulty rapidly turning hands or tapping fingers suggests cerebellar or frontal problems. NCBI
Reflex testing — Asymmetry or abnormal reflexes can help localize the lesion. Merck Manuals

C) Laboratory & pathological tests (what defines the diagnosis)

Surgical biopsy or resection with histology — Tissue under the microscope confirms a diffuse glioma and its grade. Today, the tissue diagnosis is “integrated” with molecular results for the final name. PMC
IDH1/IDH2 mutation testing — IDH mutation defines adult-type diffuse gliomas and splits them from glioblastoma IDH-wildtype; it also guides the tumor’s final name. PMC
1p/19q codeletion testing (FISH/array) — Required to diagnose oligodendroglioma; if present with IDH mutation, the tumor is oligodendroglioma, not astrocytoma. PMC
ATRX immunohistochemistry or sequencing — Loss of ATRX supports astrocytoma, IDH-mutant. SpringerLink
TP53 immunostain or sequencing — Common in IDH-mutant astrocytoma; part of the pattern separating it from oligodendroglioma. SpringerLink
MGMT promoter methylation — A predictive biomarker of better response to alkylating chemotherapy in gliomas; influences treatment planning. Cancer.gov
TERT promoter mutation — Often seen in oligodendroglioma; contributes to tumor biology (telomere maintenance). PMC

D) Electrodiagnostic tests (electrical studies)

EEG (electroencephalogram) — Records brain waves; helpful when seizures are part of the presentation or to monitor for subclinical seizures. NCBI
Visual evoked potentials (VEP) — Measures how fast signals travel from eye to visual cortex; helpful if vision pathways may be affected or during surgery to protect vision. NCBI+1

E) Imaging tests (pictures of the brain)

MRI brain with and without contrast — The main imaging test to find, size, and characterize a glioma; advanced MRI (perfusion, diffusion, spectroscopy) can add detail, and fMRI/tractography can help surgeons plan safe routes. CT is useful in emergencies (e.g., sudden headache, new seizure) or when MRI is not available. Professional imaging guidelines endorse MRI (with and without contrast) as the go-to study and note that MR spectroscopy may aid assessment. ACR Search+1

Non-pharmacological treatments

Important: choices depend on whether your tumor is now classified as astrocytoma, IDH-mutant (grade 3) or oligodendroglioma, IDH-mutant, 1p/19q-codeleted (grade 3), surgical results, age, and performance status.

Maximal safe surgical resection – removes as much tumor as safely possible to relieve pressure, reduce seizures, obtain tissue, and improve outcomes. Awake mapping helps protect critical speech/motor areas. Nature
Post-op radiotherapy (RT) – standard after resection/biopsy for grade-3 diffuse gliomas; typical total doses are around 59.4–60 Gy in small daily fractions. ASTRO+1
Precision RT planning – modern ESTRO-EANO guidance defines target volumes and safe margins for IDH-mutant grade 2–3 gliomas. Erasmus University Rotterdam
MRI-guided RT adaptation – uses serial MRI to refine fields when anatomy shifts from swelling or surgery. (Guideline context). Erasmus University Rotterdam
Tumor Treating Fields (TTFields) – a wearable device delivering low-intensity electric fields that disrupt cell division. Proven to extend survival in glioblastoma; use in grade-3 IDH-mutant tumors is investigational. PubMed+1
Seizure self-management and safety education – sleep hygiene, trigger avoidance, supervision for risky activities until seizures are controlled. (EANO seizure guidance.) PMC
Physical therapy (PT) – maintains strength, balance, and endurance; reduces falls; improves fatigue. (Supportive-care standards.) Nature
Occupational therapy (OT) – adapts daily activities and tools to preserve independence at home and work. (Supportive-care standards.) Nature
Speech-language therapy – rebuilds language, swallowing, and cognitive-communication skills after surgery or RT. (Supportive-care standards.) Nature
Neuropsychological rehabilitation – targeted cognitive exercises and compensatory strategies to aid attention, memory, and planning. (Supportive-care standards.) Nature
Palliative-care integration early – relieves symptoms (pain, fatigue, mood), coordinates care, and supports families from diagnosis onward. (EANO practice.) PMC
Psychosocial counseling – manages anxiety, depression, and role changes; improves coping and quality of life. (EANO practice.) PMC
Nutrition counseling – supports weight, strength, and healing; prevents interactions; no diet cures gliomas. NPCRC+1
Return-to-driving/work guidance – follows legal rules and safety after seizures or surgery; reassessed as control improves. (Regional guidance example.) eviQ
Fatigue management – graded exercise, energy conservation, sleep hygiene; screen for depression and thyroid issues. (Supportive-care standards.) PMC
Steroid-sparing edema measures – careful RT planning and timing, plus gradual taper of steroids to the lowest dose that controls symptoms. Alberta Health Services+1
Clinical-trial participation – access to new drugs/devices tailored to molecular markers (e.g., IDH-targeted agents). BTRT
Advance-care planning – documents preferences for care in case of emergencies or future decline. (Palliative-care standards.) PMC
Caregiver education & support groups – lowers stress, improves adherence and safety at home. (Cancer-support standards.) CGAToolkit
Vaccination review – routine non-live vaccines as advised; coordinate timing with chemo/RT. (General oncology best practice.) Cancer.gov

Drug treatments

Key principle: drug choices depend on the reclassified diagnosis.

A) If today’s diagnosis is “astrocytoma, IDH-mutant, grade 3” (1p/19q non-codeleted):

Temozolomide (TMZ) is the usual alkylating chemotherapy with RT or after RT. In the CATNON trial (non-codeleted anaplastic glioma), adjuvant TMZ after RT improved overall survival; concurrent TMZ did not add benefit. Dose/timing: 75 mg/m² daily with RT (if given concurrently), then 150–200 mg/m² daily on days 1–5 every 28 days for 6–12 cycles. Purpose: kill tumor cells. Key side-effects: low blood counts, fatigue, nausea. PMC+1

B) If today’s diagnosis is “oligodendroglioma, IDH-mutant, 1p/19q-codeleted, grade 3”:

PCV regimen (three drugs) with RT improves long-term survival versus RT alone (RTOG 9402; EORTC 26951). Schedule (classic): Lomustine (CCNU) 110 mg/m² orally day 1; Procarbazine 60 mg/m² orally days 8–21; Vincristine 1.4 mg/m² IV (max 2 mg) days 8 & 29; repeat every 6–8 weeks for up to 6 cycles, adjusted for counts. Purpose: cytotoxic combination. Key side-effects: myelosuppression, neuropathy (vincristine), nausea. PubMed+2PubMed+2

C) Medicines used across both types (treatment or symptom control):

Lomustine (CCNU) – nitrosourea (part of PCV or used alone when TMZ is not suitable). Dose: 110–130 mg/m² q6–8 weeks. Side-effects: delayed low blood counts, liver enzymes. PubMed
Procarbazine – alkylator (PCV component). Dose: ~60 mg/m² daily days 8–21 per cycle. Side-effects: myelosuppression, MAOI-like food/drug interactions. PubMed
Vincristine – microtubule inhibitor (PCV component). Dose: 1.4 mg/m² IV days 8 & 29 per cycle. Side-effects: neuropathy, constipation. PubMed
Carmustine (BCNU) – nitrosourea alternative (systemic or wafer in selected GBM; systemic use may be considered if others fail). Side-effects: lung toxicity (rare), low counts. (General PDQ overview.) Cancer.gov
Bevacizumab – anti-VEGF antibody. Does not improve survival in glioma but can reduce edema and steroid needs; considered for symptomatic control at recurrence. Dose: 10 mg/kg IV q2 weeks or 15 mg/kg q3 weeks. Side-effects: hypertension, bleeding, clots. PMC
Dexamethasone – steroid for brain swelling. Use the lowest effective dose and taper as symptoms allow to limit side-effects (sleep change, mood, high sugar, infection). Typical starts range 2–16 mg/day split doses, individualized. Alberta Health Services+1
Levetiracetam – first-line anti-seizure medicine (few interactions with chemo). Dose: often 500 mg twice daily, titrate. Side-effects: irritability, fatigue. PMC+1
Lamotrigine / Lacosamide / Topiramate – alternatives if levetiracetam not tolerated or seizures persist. Note: avoid enzyme-inducing AEDs when possible during chemo. PMC
Ondansetron (± aprepitant) – anti-nausea support during TMZ/PCV. Dose: ondansetron 8 mg before chemo then 8 mg q8–12h PRN. Side-effects: constipation, headache. (Standard antiemetic practice.) Cancer.gov
Pneumocystis (PJP) prophylaxis when using prolonged daily TMZ with RT (per local policy). Agents: trimethoprim-sulfamethoxazole. (Institutional/PDQ practice.) Cancer.gov
Proton-pump inhibitor if on steroids/NSAIDs to reduce ulcer risk. Examples: omeprazole 20 mg daily. (Supportive-care practice.) Cancer.gov
Pain control (acetaminophen ± short-course opioids) – tailored to need; avoid NSAIDs around surgery or thrombocytopenia. (Supportive-care practice.) Cancer.gov
Vorasidenib or Ivosidenib (IDH inhibitors) – approved data are for low-grade IDH-mutant diffuse glioma; use in grade-3 disease remains investigational/off-label and should be in trials. PubMed+1
Anticoagulation for tumor-related clots – only if a clot occurs; balances bleeding risk. (PDQ overview.) Cancer.gov
Psychostimulants (e.g., methylphenidate) – sometimes for severe fatigue or attention deficits, case-by-case. (Supportive-care practice.) PMC
Thyroid or endocrine replacement – if RT-related pituitary effects arise. (PDQ overview.) Cancer.gov
Antibiotics/antivirals as needed – treat intercurrent infections promptly during chemo/steroid therapy. (PDQ overview.) Cancer.gov
Bowel regimen – prevent constipation from opioids, vincristine, or reduced mobility. (Supportive-care practice.) Cancer.gov
Sleep/anxiety support (non-benzodiazepine first) – CBT-I, melatonin, or short-term meds as appropriate. (Supportive-care practice.) PMC
Vaccinations – inactivated vaccines per schedule; time around chemo per oncology advice. (PDQ overview.) Cancer.gov

Dietary molecular supplements

There is no supplement that treats or cures astrocytoma/oligodendroglioma. Nutrition supports strength and treatment tolerance. Always clear supplements with your oncology team to avoid interactions (for example, procarbazine has dietary/MAOI-like restrictions). Typical supportive items when indicated include:

Vitamin D – correct deficiency (e.g., 800–2000 IU/day, individualized). Supports bone and immune health during steroids/less activity. CGAToolkit
Calcium – if low intake or on steroids; dose per dietary assessment to protect bones. CGAToolkit
Omega-3 fatty acids – general heart/anti-inflammatory support (e.g., 1 g/day EPA+DHA if approved). Avoid before surgery due to bleeding risk. CGAToolkit
Probiotics/soluble fiber – for constipation/diarrhea management; avoid during severe neutropenia. CGAToolkit
Protein supplements – whey/plant protein to meet daily needs when appetite is low. NPCRC
Multivitamin (standard dose) – fills dietary gaps; avoid “mega-dose” antioxidants during RT/chemo. CGAToolkit
Folic acid/B-complex – nutritional repletion if documented deficiency (check meds for interactions). CGAToolkit
Electrolyte solutions – prevent dehydration with nausea/diarrhea. NPCRC
Fiber (psyllium/β-glucan) – helps bowel regularity; take apart from some meds. CGAToolkit
Caffeine in moderation – can help fatigue and headaches for some; avoid late in day if sleep is poor. (Lifestyle guidance.) NPCRC

Immunity-booster / regenerative / stem-cell drugs

There are no approved “immune-booster” or stem-cell drugs that treat these tumors. Some immune and cellular approaches are under study:

Checkpoint inhibitors (nivolumab, pembrolizumab) – did not improve survival in glioblastoma trials; use outside a trial is limited. PubMed
Cancer vaccines (e.g., dendritic-cell vaccines) – mixed/early results; consider only within clinical trials. (General trial landscape.) National Brain Tumor Society
Oncolytic viruses – several trials, but no standard role yet. (Trial landscape.) National Brain Tumor Society
CAR-T and other engineered cells – early-phase studies for targets like EGFRvIII; experimental. National Brain Tumor Society
IDH-targeted therapy (ivosidenib, vorasidenib) – approved/positive data in lower-grade IDH-mutant glioma; role in grade-3 remains investigational. PubMed+1
Supportive immune health – vaccines, nutrition, infection prevention; not anti-cancer by themselves. (PDQ overview.) Cancer.gov

Surgeries

Awake craniotomy with cortical/subcortical mapping – allows the surgeon to remove more tumor while testing speech and movement during the operation; goal is “maximal safe resection.” Nature
Standard craniotomy and resection – used when mapping is not required; removes as much tumor as safe. Nature
Stereotactic biopsy – needle biopsy to confirm the diagnosis when the tumor is not safely resectable. Nature
Repeat (second-look) resection – considered at recurrence to relieve mass effect and obtain updated tissue for molecular testing and trial eligibility. Nature
CSF shunt or endoscopic third ventriculostomy – for hydrocephalus (pressure from blocked CSF flow). Cancer.gov

Prevention tips

There is no proven way to prevent these tumors. Focus on reducing general health risks and treatment complications:

Avoid unnecessary ionizing radiation to the head. Cancer.gov
Use seatbelts/helmets and fall-prevention to avoid head injuries that could complicate care. (Public-health best practice.) Cancer.gov
Manage blood pressure, diabetes, and cholesterol. (General oncology survivorship.) Cancer.gov
Do not smoke; limit alcohol. Cancer.gov
Keep vaccines up to date (non-live, timed with therapy). Cancer.gov
Practice good hand hygiene and food safety, especially during chemo. CGAToolkit
Stay physically active as able; exercise helps fatigue and mood. PMC
Sleep 7–8 hours; treat sleep apnea if present. (Supportive-care practice.) PMC
Use seizure precautions until cleared to drive/work at heights. PMC
Discuss family/genetic risks with your team if you have multiple relatives with gliomas (rare). Cancer.gov

When to see a doctor (red flags)

Call your care team urgently for new or worsening seizures, severe or persistent headache, vision loss, weakness/numbness, trouble speaking, confusion, sudden vomiting with headache, fever on chemo, or any rapid change after a steroid taper. These can signal swelling, bleeding, infection, or recurrence and need prompt assessment. Continuum+1

What to eat and what to avoid

Eat small, frequent, protein-rich meals to fight fatigue and weight loss. NPCRC
Hydrate with water or oral rehydration solutions, especially on chemo days. NPCRC
Food-safety first if counts are low: avoid raw/undercooked meats/eggs/fish; wash produce well. CGAToolkit
No mega-dose antioxidants during RT/chemo unless your oncologist agrees. CGAToolkit
Limit alcohol; avoid with metronidazole-like interactions (e.g., procarbazine). PubMed
Mind MAOI-like restrictions on procarbazine (aged cheeses, cured meats, certain wines) to avoid blood-pressure spikes. PubMed
High-fiber foods and stool softeners to prevent constipation (vincristine, opioids). PubMed
Maintain calcium/vitamin D if on long-term steroids; consider dairy or fortified foods. Alberta Health Services
Avoid unverified herbal supplements that may thin blood or interact with chemo (e.g., St. John’s wort). (Safety guidance.) CGAToolkit
Work with an oncology dietitian to personalize a plan. NPCRC

Frequently asked questions

Is “anaplastic oligoastrocytoma” still a diagnosis?
No. It’s a historical term. Today, almost all such tumors reclassify as astrocytoma, IDH-mutant, or oligodendroglioma, IDH-mutant and 1p/19q-codeleted. PMC+1
Why does IDH status matter?
It defines tumor type, guides prognosis, and can influence treatment choices and trials. PMC
What is 1p/19q codeletion?
A chromosome signature; when present with IDH-mutation, it defines oligodendroglioma and predicts strong benefit from RT+PCV. PubMed
What’s the standard treatment for grade-3 astrocytoma (IDH-mutant)?
Surgery → RT → adjuvant temozolomide (per CATNON). PMC
What’s the standard for grade-3 oligodendroglioma (IDH-mutant, 1p/19q-codeleted)?
Surgery → RT + PCV (long-term survival benefit). PubMed
Do TTFields help these tumors?
TTFields improves survival in glioblastoma; use in grade-3 IDH-mutant tumors is investigational. PubMed
Can bevacizumab cure the tumor?
No. It can reduce swelling and steroid need, mainly for symptoms, without proven overall survival benefit. PMC
Should everyone take steroids?
Only for symptoms from brain swelling, at the lowest effective dose, then taper. Alberta Health Services
Which anti-seizure drug is preferred?
Often levetiracetam because it has fewer interactions; alternatives exist if not tolerated. PMC
Can special diets or supplements treat this tumor?
No diet or supplement treats it. Nutrition supports strength and side-effect control. CGAToolkit
Are immunotherapies helpful?
Checkpoint inhibitors have not improved survival in glioblastoma; use for these tumors is trial-based. PubMed
What about IDH inhibitors?
They have positive data in lower-grade IDH-mutant glioma; role in grade-3 disease is under study. PubMed
How is radiotherapy planned?
Modern guidelines (ESTRO-EANO/ASTRO) define target volumes and doses to balance control and safety. Erasmus University Rotterdam+1
What follow-up scans do I need?
Regular MRI (often every 2–4 months initially), plus exams; timing varies by response and regimen. (Guideline overview.) Nature
Where can I read a reliable overview?
See the NCI PDQ pages and EANO guidelines for clinician-reviewed, up-to-date summaries. Cancer.gov+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.